New once-a-month drug could treat diabetes and obesity, scientists say
Stay up to date with notifications from The Independent
Notifications can be managed in browser preferences.
Experimental drug could lead to substantial weight reduction
- A new experimental drug, Maridebart cafraglutide (MariTide), shows promise for significant weight reduction and treating obesity and type 2 diabetes.
- Clinical trial results indicate MariTide can reduce body weight by up to 20 per cent within a year, with weight loss continuing beyond 12 months.
- The drug targets similar molecules as popular weight loss jabs like Ozempic and also affects insulin release, leading to improved heart health measures.
- MariTide's once-a-month or less frequent dosing schedule could enhance patient adherence and provide sustainable, long-term weight control.
- While some mild to moderate gut-related side effects were noted, they were manageable, and researchers are now exploring the drug's further efficacy and use in other conditions.